I. POLICY STATEMENT

Coverage of Lucentis® (ranibizumab) intravitreal injection will be provided when medically indicated and in accordance with applicable state requirements and, as specific to Medicare, national and local coverage determinations. To establish medical necessity for this service, Avēsis aligns its criteria with the evidence and consensus based clinical practice guidelines set forth by the American Academy of Ophthalmology (AAO). The AAO incorporates evidence based best practice and FDA approval and/or recommendations¹. Avēsis Medical Directors and clinical staff are licensed medical professionals and review criteria and documentation submitted by requesting providers using sound medical judgment.

II. INDICATIONS AND LIMITATION OF COVERAGE

1.0 Coverage is limited to membership eligible at the time of the date of service and in accordance with continuity requirements, as applicable.

2.0 Coverage is indicated for treatment when enrollees have the following condition*:
   *Note, refer to Section V for additional required detail
   2.1 Neovascular (Wet) age-related macular degeneration (AMD)
   2.2 Diabetic macular edema (DME)
   2.3 Macular edema associated with retinal vein occlusion.

3.0 Lucentis® (ranibizumab) will not be covered at a frequency that exceeds what is medically reasonable and necessary.

4.0 Coverage will be considered only for enrollees who have completed a minimum of three (3) months of Avastin® (bevacizumab) with unsatisfactory outcome, defined as:
   4.1 Minimum 3-month treatment trial
   4.2 Fewer than 4 lines of improvement on visual acuity testing

5.0 Authorizations will be given for the time period of 12 months and will cover up to 16 injections during that time period.
   5.1 Additional injections requested will be subject to review and determinations will be made on a case-by-case basis and subject to medical necessity.
   5.2 When services are performed in excess of established parameters, they may be subject to peer and quality review.

¹American Academy of Ophthalmology https://www.aao.org
III. TREATMENT RECOMMENDATIONS

1.0 The recommended dose for Lucentis® (ranibizumab) is:
   1.1 3 mg or 5 mg intravitreal injection once every 4 weeks (monthly) for the first 12 weeks (3 months)
   1.2 Although Lucentis® may be dosed as frequently as 2 mg every 4 weeks (monthly), minimal efficacy (1-2 letter gain) was demonstrated when Lucentis® (ranibizumab) was dosed every 4 weeks as compared to every 8-12 weeks.

2.0 A medical screening and clearance should be considered for enrollees with medical comorbidities.
   2.1 Medical clearance should also be obtained when the enrollee is scheduled for any major surgery and should include when to stop the use of Lucentis® (ranibizumab) preoperatively, and when it may reasonably be restarted after surgery.

IV. MEDICAL NECESSITY IS ESTABLISHED for APPLICABLE CODE J2778

1.0 To establish medical necessity all criterion points referenced below must be clearly & legibly documented in the medical record and made available to Avēsis upon submission of request.
   1.1 Areas where ‘white out’ is used are not accepted.
   1.2 Areas with ‘black out’ or ‘scribble’ will not be accepted.
       1.2.1 A single line through text where the text will remain readable is acceptable with provider initials and date.
   2.0 Physician signature must be present on chart and procedural notes, orders, and testing interpretations.
   3.0 The submitted documentation must clearly support medical necessity as outlined in Section II Indications and Limitations of Coverage.
       3.1 Includes medical necessity rationale to change therapy from Avastin to EYLEA® (aflibercept)
   4.0 Medical documentation must clearly state the clinical indication/medical necessity for the Lucentis® (ranibizumab) injection and the frequency of its usage.
   5.0 Ocular Coherence Tomography (OCT) and/or fluorescein angiography (FA) test results must be interpreted and firmly establish/support diagnosis.
   6.0 Procedure note must include:
       6.1 Actual administered dosage of Lucentis® (ranibizumab) given
       6.2 Site of injection
       6.3 Route of administration
       6.4 Injection Lot #
       6.5 Injection expiration date
       6.6 Post-injection vision ≥ CF
   7.0 In accordance with the prescribing information for Lucentis® (ranibizumab), medical documentation must clearly display that enrollee has been queried/screened for contraindications and/or co-morbidities:
       7.1 Evidence that enrollee has been screened for medical conditions which would contraindicate the use of Lucentis® (ranibizumab), including but is not limited to:
           7.1.1 Gastrointestinal hemorrhage or perforations
           7.1.2 Other hemorrhage occurrences
           7.1.3 Wound healing complications
           7.1.4 Arterial thrombo-embolic events
           7.1.5 Hypertension
           7.1.6 Proteinuria
           7.1.7 Heart failure
8.0 Medical documentation must evidence number 7.0 above along with full informed consent, outlining all pertinent risks, inclusive of the following:

8.1 Date
8.2 Consent to perform
8.3 Consent to waive
8.4 Patient or Representative Signature

8.5 Surgeon/Physician Signature
8.6 Witness Signature

V. ICD-10 CODES SUPPORTING MEDICAL NECESSITY

1.0 For any code not listed below, please supply proper documentation with your prior authorization request, and Avēsis will review and make a determination based on medical necessity.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B39.4 – B39.9</td>
<td>Histoplasmosis capsulati, unspecified – Histoplasmosis, unspecified</td>
</tr>
<tr>
<td>E10.311</td>
<td>Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E10.3211 – E10.3219</td>
<td>Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E10.3311 – E10.3319</td>
<td>Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E10.3411 – E10.3419</td>
<td>Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E10.3511 – E10.3519</td>
<td>Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E10.37X1 – E10.37X9</td>
<td>Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment</td>
</tr>
<tr>
<td>E11.311</td>
<td>Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E11.3211 – E11.3219</td>
<td>Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E11.3311 – E11.3319</td>
<td>Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E11.3411 – E11.3419</td>
<td>Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E11.3511 – E11.3519</td>
<td>Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E11.37X1 – E11.37X9</td>
<td>Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment</td>
</tr>
<tr>
<td>H34.8110 – H34.8192</td>
<td>Central retinal vein occlusion</td>
</tr>
<tr>
<td>H34.8310 – H34.8392</td>
<td>Tributary (branch) retinal vein occlusion</td>
</tr>
<tr>
<td>H35.3210 – H35.3293</td>
<td>Exudative age-related macular degeneration</td>
</tr>
<tr>
<td>H35.351 – H35.359</td>
<td>Cystoid macular degeneration</td>
</tr>
<tr>
<td>H35.81</td>
<td>Retinal edema</td>
</tr>
</tbody>
</table>